Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Average Sales Price Final Rule Includes PhRMA’s Estimation Method

Executive Summary

The methodology for estimating drug price concessions when submitting average sales prices for Medicare Part B will follow a proposal made by drug manufacturers in comments to the interim final rule

You may also be interested in...



Panitumumab Pricing “Bookends” Will Be Avastin, Erbitux, Amgen Says

Amgen's pending oncologic panitumumab will be priced between Genentech's Avastin and Bristol-Myers Squibb/ImClone's Erbitux, Exec VP-Commercial Operations George Morrow said

Panitumumab Pricing “Bookends” Will Be Avastin, Erbitux, Amgen Says

Amgen's pending oncologic panitumumab will be priced between Genentech's Avastin and Bristol-Myers Squibb/ImClone's Erbitux, Exec VP-Commercial Operations George Morrow said

Average Sales Price Creates Inflationary Pressure, Former CMS Head Says

The use of average sales price for reimbursement of Medicare Part B-covered drugs puts inflationary pressure on drug prices, former Centers for Medicare & Medicaid Services Administrator Thomas Scully said

Related Content

Topics

UsernamePublicRestriction

Register

PS044666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel